Chesterford Research Park management team and Diagnostics for the Real World work together, re-purposing space to create efficient assembly line
News
£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park
Science Park helping to drive local economic growth with SELEP support
Situation:
The coronavirus (COVID-19) pandemic has presented an enormous challenge to individuals and organisations worldwide. Adapting to living with the threat of the SARS-CoV-2 virus among our communities has required significant changes in how we behave and operate.
Our position:
Where next for UK life sciences regulation?, Where next for the EU’s pharmaceutical strategy? International data transfers after the demise of the US Privacy Shield, Supply chain resilience, and much more…..
Sequence - July 2020 - Issue 11
- AlmirallShare launches its fifth call for proposals, aiming to establish partnerships to find new assets—new chemical entities, biologics and other advanced therapies—for the treatment of dermatological conditions
- Scientists can participate until October 31, 2020
- AlmirallShare is responsible for 50% of the private-public collaborations at Almirall. This open innovation platform has received more than 350 proposals since its launch in 2017
AMSBIO offers a comprehensive range of end-to-end services for exosome purification, characterization, and engineering.
With the expansion of two of Biocair’s North American facilities, the company’s offerings in the US have increased substantially.
The Philadelphia office has doubled in size, with a state-of-the-art cryogenic filling station to further support cell and gene therapy clients, while the expanded Boston office will allow Biocair to improve delivery and service, with greater operational capacity.
Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today provides an unaudited pre-close trading update for the six months ended 30 June 2020. The Company plans to report its half year 2020 results on 17 August 2020.
Financials
Westbury, NY – July 28, 2020 – BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it can now provide broader access to its growing inventory of plasma, serum and saliva specimens from active and recovered COVID-19 patients for use in drug, diagnostic and vaccine research.